Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDLifecore Biomedical, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.06 | -$0.06 | -$0.06 |
| Q2 2024 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2024 | 1 | -$0.50 | -$0.47 | -$0.49 |
| Q4 2024 | 1 | -$0.30 | -$0.28 | -$0.29 |
| Q1 2025 | 1 | -$0.15 | -$0.14 | -$0.15 |
| Q2 2025 | 1 | $0.00 | $0.00 | $0.00 |
| Q3 2025 | 1 | -$0.33 | -$0.30 | -$0.32 |
| Q4 2025 | 1 | -$0.21 | -$0.20 | -$0.20 |
| Q1 2026 | 1 | -$0.14 | -$0.13 | -$0.13 |
| Q2 2026 | 1 | $0.01 | $0.01 | $0.01 |
| Q3 2026 | 1 | -$0.34 | -$0.32 | -$0.33 |
| Q4 2026 | 1 | -$0.23 | -$0.21 | -$0.22 |
| Q1 2027 | 1 | -$0.16 | -$0.14 | -$0.15 |
| Q2 2027 | 1 | -$0.07 | -$0.07 | -$0.07 |
Lifecore Biomedical, Inc. Earnings Date And Information
Lifecore Biomedical, Inc. last posted its earnings results on Monday, August 26th, 2024. The company reported $-0.15 earnings per share for the quarter, missing analysts' consensus estimates of $-0.12 by $0.03. The company had revenue of 24.71 M for the quarter and had revenue of 128.26 M for the year. Lifecore Biomedical, Inc. has generated $0 earnings per share over the last year ($0.33 diluted earnings per share) and currently has a price-to-earnings ratio of 34.46. Lifecore Biomedical, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 2nd, 2025 based on prior year's report dates.
Lifecore Biomedical, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/04/2024 | Q1 2025 | -$0.53 | $23.19 M | $24.71 M | ||
| 08/26/2024 | Q4 2024 | -$0.12 | -$0.23 | -0.11 | $37.89 M | |
| 08/09/2024 | Q3 2024 | -$0.12 | $0.51 | 0.63 | $35.77 M | $35.70 M |
| 08/09/2024 | Q2 2024 | -$0.12 | $0.47 | 0.59 | $30.15 M | |
| 08/09/2024 | Q1 2024 | -$0.12 | -$0.35 | -0.23 | $24.52 M | |
| 03/19/2024 | Q4 2023 | -$1.19 | $31.55 M | |||
| 06/02/2023 | Q3 2023 | -$0.51 | $27.60 M | |||
| 03/16/2023 | Q2 2023 | -$0.04 | -$0.42 | -0.38 | $21.86 M | |
| 03/16/2023 | Q1 2023 | -$0.04 | -$0.38 | -0.34 | $43.36 M | |
| 03/16/2023 | Q4 2022 | -$0.04 | -$1.24 | -1.2 | $47.63 M | |
| 02/27/2022 | Q3 2022 | -$0.45 | $53.07 M | |||
| 11/30/2021 | Q2 2022 | -$1.30 | $129.49 M | |||
| 08/31/2021 | Q1 2022 | -$0.32 | $128.79 M | |||
| 05/31/2021 | Q4 2021 | -$0.10 | $139.83 M | |||
| 02/27/2021 | Q3 2021 | -$0.19 | $137.78 M | |||
| 11/30/2020 | Q2 2021 | -$0.47 | $130.90 M | |||
| 08/31/2020 | Q1 2021 | -$0.38 | $135.64 M | |||
| 05/31/2020 | Q4 2020 | -$0.52 | $156.13 M | |||
| 02/28/2020 | Q3 2020 | -$0.39 | $152.93 M | |||
| 11/30/2019 | Q2 2020 | -$0.23 | $142.59 M |
Lifecore Biomedical, Inc. Earnings: FAQ's
When is Lifecore Biomedical, Inc.'s earnings date?
Lifecore Biomedical, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 2nd, 2025 based off last year's report dates.
How can I listen to Lifecore Biomedical, Inc.'s earnings conference
call?
The conference call for Lifecore Biomedical, Inc.'s latest earnings report can be listened to online.
How can I read Lifecore Biomedical, Inc.'s conference call transcript?
The conference call transcript for Lifecore Biomedical, Inc.'s latest earnings report can be read online.
How much revenue does Lifecore Biomedical, Inc. generate each year?
Lifecore Biomedical, Inc. (:LFCR) has a recorded annual revenue of $128.26 M.
How much profit does Lifecore Biomedical, Inc. generate each year?
Lifecore Biomedical, Inc. (:LFCR) has a recorded net income of $128.26 M. Lifecore Biomedical, Inc. has generated $0.39 earnings per share over the last four quarters.
What is Lifecore Biomedical, Inc.'s price-to-earnings ratio?
Lifecore Biomedical, Inc. (:LFCR) has a price-to-earnings ratio of 34.46 and price/earnings-to-growth ratio is -0.77.